PTC Therapeutics (NASDAQ:PTCT) Releases Earnings Results, Beats Estimates By $0.68 EPS

Posted by Francis Steltz on Jul 30th, 2026

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.68, Zacks reports. PTC Therapeutics had a negative net margin of 22.58% and a negative return on equity of 362.45%. The company had revenue of $360.52 million during the quarter, compared to the consensus estimate of $298.63 million.

Here are the key takeaways from PTC Therapeutics’ conference call:

Record results and raised guidance: Second-quarter total revenue reached $361 million, including $239 million in product revenue, prompting PTC to raise 2026 product revenue guidance to $850 million–$950 million and total revenue guidance to $1.18 billion–$1.28 billion. Management believes the company may reach cash-flow breakeven in 2026.
Sephience launch momentum remains strong: Global Sephience revenue grew 21% sequentially to approximately $151 million, with 1,647 patients on commercial therapy by quarter-end and prescriptions from all U.S. centers of excellence. Japan is ramping quickly, while early-access programs in Europe and other regions are expected to contribute more meaningfully in late 2026 and 2027.
Patient retention and demand metrics support management’s long-term outlook for Sephience: prescription renewal rates exceed 90%, discontinuations are approximately 20%, and uptake spans treatment-naive patients, prior-therapy failures, switches, and multiple disease severities. PTC continues to project a global commercial opportunity exceeding $2 billion.
Pipeline progress: Novartis has begun enrolling the approximately 770-patient phase III INVEST-HD study of votoplam, while PTC and Novartis plan to discuss the 24-month data with the FDA in the second half of 2026, including potential accelerated approval pathways. PTC also expects to start the PROVE FA study of vatiquinone in the third quarter and advance its NLRP3, DHODH, and MSH3 programs.
Strong liquidity but ongoing DMD pressure: Cash, equivalents, and marketable securities totaled $2.23 billion after refinancing most 2026 convertible notes with 0% notes due 2031, supporting potential business development activity. However, the Duchenne franchise faces generic pressure on Emflaza, while Translarna sales continue in certain markets despite regulatory and licensing challenges in Europe.

PTC Therapeutics Stock Up 1.4%

NASDAQ PTCT traded up $1.03 during trading on Thursday, hitting $75.52. 1,373,852 shares of the stock traded hands, compared to its average volume of 1,459,786. PTC Therapeutics has a 12-month low of $43.17 and a 12-month high of $90.87. The firm has a 50-day simple moving average of $77.47 and a 200-day simple moving average of $72.79. The company has a market capitalization of $6.26 billion, a P/E ratio of -32.41, a price-to-earnings-growth ratio of 6.56 and a beta of 0.53.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PTCT shares. Weiss Ratings downgraded PTC Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Raymond James Financial assumed coverage on shares of PTC Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $108.00 price objective for the company. Zacks Research upgraded shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Cantor Fitzgerald boosted their target price on shares of PTC Therapeutics from $124.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. Finally, Royal Bank Of Canada upped their target price on shares of PTC Therapeutics from $82.00 to $85.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $93.83.

Check Out Our Latest Stock Report on PTC Therapeutics

Insider Transactions at PTC Therapeutics

In other news, VP Mark Elliott Boulding sold 5,079 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $85.08, for a total transaction of $432,121.32. Following the sale, the vice president directly owned 105,272 shares in the company, valued at approximately $8,956,541.76. This represents a 4.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary L. Smith sold 15,834 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $90.00, for a total transaction of $1,425,060.00. Following the completion of the transaction, the director directly owned 21,813 shares of the company’s stock, valued at approximately $1,963,170. The trade was a 42.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 198,662 shares of company stock valued at $16,347,994 in the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. purchased a new position in shares of PTC Therapeutics during the 3rd quarter worth about $508,000. Bank of Montreal Can bought a new stake in PTC Therapeutics in the fourth quarter worth about $442,000. Kotler Kevin purchased a new position in shares of PTC Therapeutics during the fourth quarter valued at approximately $380,000. FORA Capital LLC bought a new position in shares of PTC Therapeutics during the third quarter valued at approximately $358,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of PTC Therapeutics by 331.5% in the second quarter. Tower Research Capital LLC TRC now owns 7,309 shares of the biopharmaceutical company’s stock worth $357,000 after buying an additional 5,615 shares during the period.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.